Now you can get on with your day after routine dental procedures, thanks to a new product that reverses the effects of local anesthesia. This new measure of comfort is for patients who dislike the lingering numbness that can last for three to five hours after leaving our office.
To deliver superior care, we're always finding better ways to ensure your comfort and improve your dental experience. OraVerse™ is the first and only product proven safe and effective in accelerating a return to normal sensation and function after a local anesthetic containing a vasoconstrictor has been used. So now in about half the time, you'll be talking, smiling and drinking just like normal.1 And OraVerse™ can benefit nearly any patient, but is not recommended for children under six years of age or weighing less than 15 kg (33 lbs).
We want you to have the most comfortable experience possible. It's a commitment that begins when you walk in the door and extends long after you leave. So if you're among the many patients who dislike lingering numbness and its limitations, let's discuss whether OraVerse™ is the right choice for you during your next dental visit.
To deliver superior care, we're always finding better ways to ensure your comfort and improve your dental experience. OraVerse™ is the first and only product proven safe and effective in accelerating a return to normal sensation and function after a local anesthetic containing a vasoconstrictor has been used. So now in about half the time, you'll be talking, smiling and drinking just like normal.1 And OraVerse™ can benefit nearly any patient, but is not recommended for children under six years of age or weighing less than 15 kg (33 lbs).
We want you to have the most comfortable experience possible. It's a commitment that begins when you walk in the door and extends long after you leave. So if you're among the many patients who dislike lingering numbness and its limitations, let's discuss whether OraVerse™ is the right choice for you during your next dental visit.
Important Safety Information
Tachycardia, bradycardia, and cardiac arrhythmias may occur with the use of phentolamine or other alpha-adrenergic blocking agents. Although such effects are uncommon with OraVerse™ (phentolamine mesylate), clinicians should be alert to the signs and symptoms of these events, particularly in patients with a history of cardiovascular disease. Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse™, myocardial infarction, and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states.
**1 Median time to recovery of normal sensation was reduced by 85 minutes (55%) in the mandible and by 83 minutes (62%) in the maxilla compared to control. Median time to recovery of normal function was reduced by 60 minutes (50%) in the mandible and by 45 minutes (43%) in the maxilla.
